Bullish & Foolish
Full BTAI fundamentals All 466 on the Survival Watch

BTAIBioXcel Therapeutics, Inc.

Is BioXcel Therapeutics struggling financially?

Yes, by its own account. BioXcel Therapeutics told the SEC on 15 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

13/100

Critical

Sector
Biotech/Pharma
Market cap
$25.2M
Source filing
10-Q 15 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 2months

    If the burn speeds up

    Empty by Aug 2026

  • 4months

    If it eases off

    Empty by Oct 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$12.8M

÷

Cash burned over the last 12 months

$57.6M

What BioXcel Therapeutics told the SEC

…our common stock. The principal risks and uncertainties affecting our business include the following: We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern. We have a limited operating history and have not generated substantial product revenues to date, which may make it difficult to evaluate the success of our business to date and to…

BioXcel Therapeutics, Inc., Form 10-Q, filed 15 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 324.7% share-count increase The company issued stock. Each share now owns 76.5% less of the business than a year ago, before any change in the price.
  • Debt pressure is material Operating earnings cover only -3.0x the interest bill, so the interest is being met out of cash reserves rather than out of the business.
  • Cash burn is narrowing It is spending 47% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt